The life sciences M&A landscape in the first quarter of 2026 was defined by constrained capital markets, heightened investor selectivity, and increasingly sophisticated transaction structures. With a slow IPO market and traditional financing sources limited, companies turned to alternative capital solutions and innovative deal frameworks to advance pipelines and achieve strategic objectives. In this environment, acquirers are prioritizing assets with credible commercialization pathways and reduced development risk. Given this focus, creative deal structuring helps reduce risk and protect value.
Read the full article: M&A Considerations Across the Evolving Life Sciences Sector //
Source: https://www.lexology.com/library/detail.aspx?g=0cf0ccda-c1ab-409f-824c-2d6516b6a616